论文部分内容阅读
目的探讨诺和龙联合二甲双胍治疗2型糖尿病的临床疗效。方法回顾分析45例患者的临床资料。结果用药2个月时患者的糖化血红蛋白情况:治疗组降至5.2%~5.7%,对照组降至6.5%~7.0%;与单用二甲双胍相比,诺和龙与二甲双胍联合应用,可使空腹血糖、餐后2 h血糖及糖化血红蛋白下降幅度增大,尤其是餐后2 h血糖的下降幅度更大,且使糖化血红蛋白降至正常。治疗过程中两组患者均未出现低血糖反应。结论诺和龙联合二甲双胍降糖效果显著,值得临床应用。
Objective To investigate the clinical efficacy of Novolin combined with metformin in the treatment of type 2 diabetes mellitus. Methods The clinical data of 45 patients were retrospectively analyzed. Results The patients’ glycosylated hemoglobin at two months after treatment was decreased from 5.2% to 5.7% in the treatment group and from 6.5% to 7.0% in the control group. Compared with metformin alone, combination of Novolin and metformin resulted in fasting Blood glucose, 2 h postprandial blood glucose and glycosylated hemoglobin decreased, especially 2 h postprandial blood glucose decreased more, and to glycated hemoglobin to normal. During the course of treatment, no hypoglycemia occurred in both groups. Conclusion Novo-longan combined metformin hypoglycemic effect is significant, it is worth clinical application.